[4]
Csermely, P.; Agoston, V.; Pongor, S. The efficiency of multi-target drugs: The network approach might help drug design. Trends Pharmacol. Sci., 2005, 26(4), 178-182.
[5]
Lipton, S.A. Turning down, but not off. Nature, 2004, 428(6982), 473.
[6]
Rogawski, M.A. Low affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents--toward an understanding of their favorable tolerability. Amino Acids, 2000, 19(1), 133-149.
[7]
Longo, M.G.; Vairo, F.; Souza, C.F.; Giugliani, R.; Vedolin, L.M. Brain imaging and genetic risk in the pediatric population, part 1: inherited metabolic diseases. Neuroimaging Clin. N. Am., 2015, 25(1), 31-51.
[8]
Kalache, A.; Keller, I. Ageing in developing countries.Increasing longevity: medical, social and political implications; Tallis, R., Ed.; Royal College of Physicians of London: London, 1998, pp. 69-80.
[10]
Chen, S.Y.; Chen, Y.; Li, Y.P.; Chen, S.H.; Tan, J.H.; Ou, T.M.; Gu, L.Q.; Huang, Z.S. Design, synthesis, and biological evaluation of curcumin analogues as multifunctional agents for the treatment of Alzheimer’s disease. Bioorg. Med. Chem., 2011, 19(18), 5596-5604.
[11]
Ray, B.; Lahiri, D.K. Neuroinflammation in Alzheimer’s disease: Different molecular targets and potential therapeutic agents including curcumin. Curr. Opin. Pharmacol., 2009, 9(4), 434-444.
[12]
Viegas, F.P.D.; Simões, M.C.R.; Rocha, M.D.; Castelli, M.R.; Moreira, M.S. Viegas, Junior, C. Doença de Alzheimer: caracterização, evolução e implicações do processo neuroinflamatório. Rev. Virtual Quim., 2011, 3, 286-306.
[13]
Palsson, B. Methods for identifying drug targets based on genomic sequence data. US Patent 20020012939, 2001.
[14]
Cornish-Bowden, A.; Cárdenas, M.L. Metabolic analysis in drug design. C. R. Biol., 2003, 326(5), 509-515.
[15]
Youdim, M.B.H.; Buccafusco, J.J. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci., 2005, 26(1), 27-35.
[16]
Bolognesi, M.L.; Matera, R.; Minarini, A.; Rosini, M.; Melchiorre, C. Alzheimer’s disease: New approaches to drug discovery. Curr. Opin. Chem. Biol., 2009, 13(3), 303-308.
[17]
Piau, A.; Nourhashémi, F.; Hein, C.; Caillaud, C.; Vellas, B. Progress in the development of new drugs in Alzheimer’s disease. J. Nutr. Health Aging, 2011, 15(1), 45-57.
[18]
Cavalli, A.; Bolognesi, M.L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem., 2008, 51(3), 347-372.
[19]
Costantino, L.; Barlocco, D. Challenges in the design of multitarget drugs against multifactorial pathologies: A new life for medicinal chemistry? Future Med. Chem., 2013, 5(1), 5-7.
[20]
Korcsmáros, T.; Szalay, M.S.; Böde, C.; Kovács, I.A.; Csermely, P. How to design multi-target drugs. Expert Opin. Drug Discov., 2007, 2(6), 799-808.
[21]
Hughes, R.E.; Nikolic, K.; Ramsay, R.R. One for all hitting multiple alzheimer’s disease targets with one drug. Front. Neurosci., 2016, 10, 177.
[22]
Ekins, S.; Mestres, J.; Testa, B. In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. Br. J. Pharmacol., 2007, 152(1), 9-20.
[23]
Scotti, L.; Filho, F.J.; de Moura, R.O.; Ribeiro, F.F.; Ishiki, H.; da Silva, M.S.; Filho, J.M.; Scotti, M.T. Multi-target drugs for neglected diseases. Curr. Pharm. Des., 2016, 22(21), 3135-3163.
[24]
Scotti, L.; Ishiki, H.; Mendonça Júnior, F.J.; Da Silva, M.S.; Scotti, M.T. In-silico analyses of natural products on leishmania enzyme targets. Mini Rev. Med. Chem., 2015, 15(3), 253-269.
[25]
Scotti, L.; Mendonca, F.J., Junior; Ishiki, H.M.; Ribeiro, F.F.; Singla, R.K.; Barbosa Filho, J.M.; Da Silva, M.S.; Scotti, M.T. Docking studies for multi-target drugs. Curr. Drug Targets, 2017, 18(5), 592-604.
[26]
Mendonça Júnior, F.J.; Scotti, L.; Ishiki, H.; Botelho, S.P.S.; Da Silva, M.S.; Scotti, M.T. Benzo- and thienobenzo- diazepines: multi-target drugs for CNS disorders. Mini Rev. Med. Chem., 2015, 15(8), 630-647.
[27]
Scotti, L.; Bezerra Mendonça, F.J., Junior; Magalhaes Moreira, D.R.; da Silva, M.S.; Pitta, I.R.; Scotti, M.T. SAR, QSAR and docking of anticancer flavonoids and variants: a review. Curr. Top. Med. Chem., 2012, 12(24), 2785-2809.
[28]
Hopkins, A.L. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol., 2008, 4(11), 682-690.
[29]
Wishart, D.S.; Knox, C.; Guo, A.C.; Shrivastava, S.; Hassanali, M.; Stothard, P.; Chang, Z.; Woolsey, J. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res., 2006, 34(Database issue), D668-D672.
[30]
Wunberg, T.; Hendrix, M.; Hillisch, A.; Lobell, M.; Meier, H.; Schmeck, C.; Wild, H.; Hinzen, B. Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits. Drug Discov. Today, 2006, 11(3-4), 175-180.
[31]
Ma, X.H.; Shi, Z.; Tan, C.; Jiang, Y.; Go, M.L.; Low, B.C.; Chen, Y.Z. In-silico approaches to multi-target drug discovery: Computer aided multi-target drug design, multi-target virtual screening. Pharm. Res., 2010, 27(5), 739-749.
[32]
Knight, J.; Nigam, Y.; Andrade, M. Diabetes management 1: Disease types, symptoms and diagnosis. Nurs. Times, 2017, 113(4), 40-44.
[33]
Bluestone, J.A.; Herold, K.; Eisenbarth, G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature, 2010, 464(7293), 1293-1300.
[34]
Lin, Y.; Sun, Z. Current views on type 2 diabetes. J. Endocrinol., 2010, 204(1), 1-11.
[35]
Stumvoll, M.; Goldstein, B.J.; van Haeften, T.W. Type 2 diabetes: principles of pathogenesis and therapy. Lancet, 2005, 365(9467), 1333-1346.
[36]
Gu, J.; Zhang, H.; Chen, L.; Xu, S.; Yuan, G.; Xu, X. Drug-target network and polypharmacology studies of a Traditional Chinese Medicine for type II diabetes mellitus. Comput. Biol. Chem., 2011, 35(5), 293-297.
[37]
Sengupta, U.; Ukil, S.; Dimitrova, N.; Agrawal, S. Expression-based network biology identifies alteration in key regulatory pathways of type 2 diabetes and associated risk/complications. PLoS One, 2009, 4(12), e8100.
[38]
Smith, S.C., Jr Multiple risk factors for cardiovascular disease and diabetes mellitus. Am. J. Med., 2007, 120(3)(Suppl. 1), S3-S11.
[39]
Mazzone, T.; Chait, A.; Plutzky, J. Cardiovascular disease risk in type 2 diabetes mellitus: Insights from mechanistic studies. Lancet, 2008, 371(9626), 1800-1809.
[40]
Tian, S.; Li, Y.; Li, D.; Xu, X.; Wang, J.; Zhang, Q.; Hou, T. Modeling compound-target interaction network of traditional Chinese medicines for type II diabetes mellitus: insight for polypharmacology and drug design. J. Chem. Inf. Model., 2013, 53(7), 1787-1803.
[41]
Kahn, S.E.; Cooper, M.E.; Del Prato, S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet, 2014, 383(9922), 1068-1083.
[42]
Wishart, D.S.; Knox, C.; Guo, A.C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. DrugBank: A knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res., 2008, 36(Database issue), D901-D906.
[43]
Kanehisa, M.; Goto, S.; Furumichi, M.; Tanabe, M.; Hirakawa, M. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res., 2010, 38(Database issue), D355-D360.
[44]
Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. The protein data bank. Nucleic Acids Res., 2000, 28(1), 235-242.
[45]
Tian, S.; Li, Y.; Wang, J.; Xu, X.; Xu, L.; Wang, X.; Chen, L.; Hou, T. Drug-likeness analysis of traditional Chinese medicines: 2. Characterization of scaffold architectures for drug-like compounds, non-drug-like compounds, and natural compounds from traditional Chinese medicines. J. Cheminform., 2013, 5(1), 5.
[46]
Zhu, F.; Shi, Z.; Qin, C.; Tao, L.; Liu, X.; Xu, F.; Zhang, L.; Song, Y.; Liu, X.; Zhang, J.; Han, B.; Zhang, P.; Chen, Y. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res., 2012, 40(Database issue), D1128-D1136.
[47]
Moller, D.E. New drug targets for type 2 diabetes and the metabolic syndrome. Nature, 2001, 414(6865), 821-827.
[48]
Qiao, X.; Hou, T.; Zhang, W.; Guo, S.; Xu, X. A 3D structure database of components from Chinese traditional medicinal herbs. J. Chem. Inf. Comput. Sci., 2002, 42(3), 481-489.
[49]
Shen, M.; Tian, S.; Li, Y.; Li, Q.; Xu, X.; Wang, J.; Hou, T. Drug-likeness analysis of traditional Chinese medicines: 1. property distributions of drug-like compounds, non-drug-like compounds and natural compounds from traditional Chinese medicines. J. Cheminform., 2012, 4(1), 31.
[50]
Tian, S.; Wang, J.; Li, Y.; Xu, X.; Hou, T. Drug-likeness analysis of traditional Chinese medicines: Prediction of drug-likeness using machine learning approaches. Mol. Pharm., 2012, 9(10), 2875-2886.
[51]
Chen, C.Y-C. TCM Database@Taiwan: The world’s largest traditional Chinese medicine database for drug screening in silico. PLoS One, 2011, 6(1), e15939.
[52]
Wang, F-R.; Yang, X-W.; Zhang, Y.; Liu, J-X.; Yang, X-B.; Liu, Y.; Shi, R-B. Three new isoflavone glycosides from Tongmai granules. J. Asian Nat. Prod. Res., 2011, 13(4), 319-329.
[53]
Liu, L.; Ma, Y.; Wang, R.L.; Xu, W.R.; Wang, S.Q.; Chou, K.C. Find novel dual-agonist drugs for treating type 2 diabetes by means of cheminformatics. Drug Des. Devel. Ther., 2013, 7, 279-288.
[54]
Markt, P.; Schuster, D.; Kirchmair, J.; Laggner, C.; Langer, T. Pharmacophore modeling and parallel screening for PPAR ligands. J. Comput. Aided Mol. Des., 2007, 21(10-11), 575-590.
[55]
Xu, H.E.; Lambert, M.H.; Montana, V.G.; Plunket, K.D.; Moore, L.B.; Collins, J.L.; Oplinger, J.A.; Kliewer, S.A.; Gampe, R.T., Jr; McKee, D.D.; Moore, J.T.; Willson, T.M. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. USA, 2001, 98(24), 13919-13924.
[56]
Waites, C.R.; Dominick, M.A.; Sanderson, T.P.; Schilling, B.E. Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist. Toxicol. Sci., 2007, 100(1), 248-258.
[57]
Heppner, T.J.; Bonev, A.D.; Eckman, D.M.; Gomez, M.F.; Petkov, G.V.; Nelson, M.T. Novel PPARgamma agonists GI 262570, GW 7845, GW 1929, and pioglitazone decrease calcium channel function and myogenic tone in rat mesenteric arteries. Pharmacology, 2005, 73(1), 15-22.
[58]
Pavankuamr, V.V.; Vinu, C.A.; Mullangi, R.; Srinivas, N.R. Preclinical pharmacokinetics and interspecies scaling of ragaglitazar, a novel biliary excreted PPAR dual activator. Eur. J. Drug Metab. Pharmacokinet., 2007, 32(1), 29-37.
[59]
Skrumsager, B.K.; Nielsen, K.K.; Müller, M.; Pabst, G.; Drake, P.G.; Edsberg, B. Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J. Clin. Pharmacol., 2003, 43(11), 1244-1256.
[60]
Chakrabarti, R.; Vikramadithyan, R.K.; Misra, P.; Hiriyan, J.; Raichur, S.; Damarla, R.K.; Gershome, C.; Suresh, J.; Rajagopalan, R. Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Br. J. Pharmacol., 2003, 140(3), 527-537.
[61]
Wang, X.J.; Zhang, J.; Wang, S.Q.; Xu, W.R.; Cheng, X.C.; Wang, R.L. Identification of novel multitargeted PPARα/γ/δ pan agonists by core hopping of rosiglitazone. Drug Des. Devel. Ther., 2014, 8, 2255-2262.
[62]
Cronet, P.; Petersen, J.F.; Folmer, R.; Blomberg, N.; Sjöblom, K.; Karlsson, U.; Lindstedt, E.L.; Bamberg, K. Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. Structure, 2001, 9(8), 699-706.
[63]
Nolte, R.T.; Wisely, G.B.; Westin, S.; Cobb, J.E.; Lambert, M.H.; Kurokawa, R.; Rosenfeld, M.G.; Willson, T.M.; Glass, C.K.; Milburn, M.V. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature, 1998, 395(6698), 137-143.
[64]
Oyama, T.; Toyota, K.; Waku, T.; Hirakawa, Y.; Nagasawa, N.; Kasuga, J.I.; Hashimoto, Y.; Miyachi, H.; Morikawa, K. Adaptability and selectivity of human peroxisome proliferator-activated receptor (PPAR) pan agonists revealed from crystal structures. Acta Crystallogr. D Biol. Crystallogr., 2009, 65(Pt 8), 786-795.
[65]
Navarrete-Vázquez, G.; Torres-Gómez, H.; Hidalgo-Figueroa, S.; Ramírez-Espinosa, J.J.; Estrada-Soto, S.; Medina-Franco, J.L.; León-Rivera, I.; Alarcón-Aguilar, F.J.; Almanza-Pérez, J.C. Synthesis, in vitro and in silico studies of a PPARγ and GLUT-4 modulator with hypoglycemic effect. Bioorg. Med. Chem. Lett., 2014, 24(18), 4575-4579.
[66]
Hidalgo-Figueroa, S.; Ramírez-Espinosa, J.J.; Estrada-Soto, S.; Almanza-Pérez, J.C.; Román-Ramos, R.; Alarcón-Aguilar, F.J.; Hernández-Rosado, J.V.; Moreno-Díaz, H.; Díaz-Coutiño, D.; Navarrete-Vázquez, G. Discovery of thiazolidine-2,4-dione/biphenylcarbonitrile hybrid as dual PPAR α/γ modulator with antidiabetic effect: in vitro, in silico and in vivo approaches. Chem. Biol. Drug Des., 2013, 81(4), 474-483.
[67]
Navarrete-Vázquez, G.; Paoli, P.; León-Rivera, I.; Villalobos-Molina, R.; Medina-Franco, J.L.; Ortiz-Andrade, R.; Estrada-Soto, S.; Camici, G.; Diaz-Coutiño, D.; Gallardo-Ortiz, I.; Martinez-Mayorga, K.; Moreno-Díaz, H. Synthesis, in vitro and computational studies of protein tyrosine phosphatase 1B inhibition of a small library of 2-arylsulfonylaminobenzothiazoles with antihyperglycemic activity. Bioorg. Med. Chem., 2009, 17(9), 3332-3341.
[68]
Torres-Piedra, M.; Ortiz-Andrade, R.; Villalobos-Molina, R.; Singh, N.; Medina-Franco, J.L.; Webster, S.P.; Binnie, M.; Navarrete-Vázquez, G.; Estrada-Soto, S. A comparative study of flavonoid analogues on streptozotocin-nicotinamide induced diabetic rats: quercetin as a potential antidiabetic agent acting via 11beta-hydroxysteroid dehydrogenase type 1 inhibition. Eur. J. Med. Chem., 2010, 45(6), 2606-2612.
[69]
Navarrete-Vázquez, G.; Alaniz-Palacios, A.; Hidalgo-Figueroa, S.; González-Acevedo, C.; Ávila-Villarreal, G.; Estrada-Soto, S.; Webster, S.P.; Medina-Franco, J.L.; López-Vallejo, F.; Guerrero-Álvarez, J.; Tlahuext, H. Discovery, synthesis and in combo studies of a tetrazole analogue of clofibric acid as a potent hypoglycemic agent. Bioorg. Med. Chem. Lett., 2013, 23(11), 3244-3247.
[70]
Abirami, N.; Natarajan, B. Isolation and Characterization of (4Z, 12Z)- Cyclopentadeca-4, 12-Dienone from Indian Medicinal Plant Grewia hirsuta and its Hyperglycemic Effect on 3 T3 and L6 Cell Lines. IJPPR, 2014, 6(2), 393-398.
[71]
Natarajan, A.; Sugumar, S.; Bitragunta, S.; Balasubramanyan, N. Molecular docking studies of (4Z, 12Z)-cyclopentadeca-4, 12-dienone from Grewia hirsuta with some targets related to type 2 diabetes. BMC Complement. Altern. Med., 2015, 15, 73.
[72]
Begum, A.; Begum, S.; Kvsrg, P.; Bharathi, K. In silico studies on functionalized azaglycine derivatives containing 2,4-thiazolidinedione scaffold on multiple targets. Int. J. Pharm. Pharm. Sci., 2017, 9(8), 209-215.
[73]
Kaladhar, D.S.V.G.K.; Yarla, N.S.; Anusha, N. Functional analysis and molecular docking studies of medicinal compounds for AChE and BChE in alzheimer’s disease and Type 2 diabetes mellitus. Aging Dis., 2013, 4(4), 186-200.
[74]
Zhang, Z.Y.; Wang, M.W. Obesity, a health burden of a global nature. Acta Pharmacol. Sin., 2012, 33(2), 145-147.
[75]
Jen, H.C.; Rickard, D.G.; Shew, S.B.; Maggard, M.A.; Slusser, W.M.; Dutson, E.P.; DeUgarte, D.A. Trends and outcomes of adolescent bariatric surgery in California, 2005-2007. Pediatrics, 2010, 126(4), e746-e753.
[76]
Obesity and overweight. WHO fact sheet N° 311. World Health Organization website; World Health Organization: Geneva, Switzerland, 2015.
[77]
Colon-Gonzalez, F.; Kim, G.W.; Lin, J.E.; Valentino, M.A.; Waldman, S.A. Obesity pharmacotherapy: what is next? Mol. Aspects Med., 2013, 34(1), 71-83.
[79]
Heal, D.J.; Gosden, J.; Smith, S.L. What is the prognosis for new centrally-acting anti-obesity drugs? Neuropharmacology, 2012, 63(1), 132-146.
[80]
Prentice, A.M.; Jebb, S.A. Obesity in Britain: Gluttony or sloth? BMJ, 1995, 311(7002), 437-439.
[81]
Deedwania, P.C. Metabolic syndrome and vascular disease: Is nature or nurture leading the new epidemic of cardiovascular disease? Circulation, 2004, 109(1), 2-4.
[82]
Patel, D. Pharmacotherapy for the management of obesity. Metabolism, 2015, 64(11), 1376-1385.
[83]
Block, J.P.; Scribner, R.A.; DeSalvo, K.B. Fast food, race/ethnicity, and income: a geographic analysis. Am. J. Prev. Med., 2004, 27(3), 211-217.
[84]
Bowman, S.A.; Gortmaker, S.L.; Ebbeling, C.B.; Pereira, M.A.; Ludwig, D.S. Effects of fast-food consumption on energy intake and diet quality among children in a national household survey. Pediatrics, 2004, 113(1 Pt 1), 112-118.
[85]
Jensen, M.D.; Ryan, D.H.; Apovian, C.M.; Ard, J.D.; Comuzzie, A.G.; Donato, K.A.; Hu, F.B.; Hubbard, V.S.; Jakicic, J.M.; Kushner, R.F.; Loria, C.M.; Millen, B.E.; Nonas, C.A.; Pi-Sunyer, F.X.; Stevens, J.; Stevens, V.J.; Wadden, T.A.; Wolfe, B.M.; Yanovski, S.Z.; Jordan, H.S.; Kendall, K.A.; Lux, L.J.; Mentor-Marcel, R.; Morgan, L.C.; Trisolini, M.G.; Wnek, J.; Anderson, J.L.; Halperin, J.L.; Albert, N.M.; Bozkurt, B.; Brindis, R.G.; Curtis, L.H.; DeMets, D.; Hochman, J.S.; Kovacs, R.J.; Ohman, E.M.; Pressler, S.J.; Sellke, F.W.; Shen, W.K.; Smith, S.C., Jr; Tomaselli, G.F. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and The obesity society. Circulation, 2014, 129(25)(Suppl. 2), S102-S138.
[86]
Shrager, B.; Jibara, G.A.; Tabrizian, P.; Roayaie, S.; Ward, S.C. Resection of nonalcoholic steatohepatitis-associated hepatocellular carcinoma: a Western experience. Int. J. Surg. Oncol., 2012, 2012915128.
[87]
Calle, E.E.; Rodriguez, C.; Walker-Thurmond, K.; Thun, M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med., 2003, 348(17), 1625-1638.
[88]
Hall, J.E.; do Carmo, J.M.; da Silva, A.A.; Wang, Z.; Hall, M.E. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ. Res., 2015, 116(6), 991-1006.
[89]
Guh, D.P.; Zhang, W.; Bansback, N.; Amarsi, Z.; Birmingham, C.L.; Anis, A.H. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health, 2009, 9(1), 88.
[90]
Polonsky, K.S.; Klein, S. Gastric banding to treat obesity: Band-aid or breakthrough? Nat. Clin. Pract. Endocrinol. Metab., 2008, 4(8), 421.
[91]
Al-Muammar, M.N.; Khan, F. Obesity: The preventive role of the pomegranate (Punica granatum). Nutrition, 2012, 28(6), 595-604.
[92]
Meye, F.J.; Trezza, V.; Vanderschuren, L.J.; Ramakers, G.M.J.; Adan, R.A.H. Neutral antagonism at the cannabinoid 1 receptor: A safer treatment for obesity. Mol. Psychiatry, 2013, 18(12), 1294-1301.
[93]
James, W.P.T.; Caterson, I.D.; Coutinho, W.; Finer, N.; Van Gaal, L.F.; Maggioni, A.P.; Torp-Pedersen, C.; Sharma, A.M.; Shepherd, G.M.; Rode, R.A.; Renz, C.L. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N. Engl. J. Med., 2010, 363(10), 905-917.
[94]
Ioannides-Demos, L.L.; Piccenna, L.; McNeil, J.J. Pharmacotherapies for obesity: past, current, and future therapies. J. Obes., 2011, 2011179674.
[95]
Yanovski, S.Z.; Yanovski, J.A. Long-term drug treatment for obesity: A systematic and clinical review. JAMA, 2014, 311(1), 74-86.
[96]
Bellido, D. Sobrepeso y obesidad: el future del tratamiento de la obesidad. Libro Obesidad y Sobrepeso de La SEEDO, 2015, 3, 3-4.
[97]
Solas, M.; Milagro, F.I.; Martínez-Urbistondo, D.; Ramirez, M.J.; Martínez, J.A. Precision obesity treatments including pharmacogenetic and nutrigenetic approaches. Trends Pharmacol. Sci., 2016, 37(7), 575-593.
[98]
van Bloemendaal, L.; Ten Kulve, J.S.; la Fleur, S.E.; Ijzerman, R.G.; Diamant, M. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J. Endocrinol., 2014, 221(1), T1-T16.
[99]
Smith, S.M.; Meyer, M.; Trinkley, K.E. Phentermine/topiramate for the treatment of obesity. Ann. Pharmacother., 2013, 47(3), 340-349.
[100]
Ali, K.F.; Shukla, A.P.; Aronne, L.J. Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity. Expert Rev. Clin. Pharmacol., 2016, 9(1), 27-34.
[101]
Sweeting, A.N.; Tabet, E.; Caterson, I.D.; Markovic, T.P. Management of obesity and cardiometabolic risk - role of phentermine/extended release topiramate. Diabetes Metab. Syndr. Obes., 2014, 7, 35-44.
[102]
Vorsanger, M.H.; Subramanyam, P.; Weintraub, H.S.; Lamm, S.H.; Underberg, J.A.; Gianos, E.; Goldberg, I.J.; Schwartzbard, A.Z. Cardiovascular effects of the new weight loss agents. J. Am. Coll. Cardiol., 2016, 68(8), 849-859.
[103]
Rodgers, R.J.; Tschöp, M.H.; Wilding, J.P. Anti-obesity drugs: Past, present and future. Dis. Model. Mech., 2012, 5(5), 621-626.
[104]
Gadde, K.M.; Allison, D.B. Combination pharmaceutical therapies for obesity. Expert Opin. Pharmacother., 2009, 10(6), 921-925.
[105]
Kakkar, A.K.; Dahiya, N. Drug treatment of obesity: current status and future prospects. Eur. J. Intern. Med., 2015, 26(2), 89-94.
[106]
Greenway, F.L.; Bray, G.A. Combination drugs for treating obesity. Curr. Diab. Rep., 2010, 10(2), 108-115.
[107]
Roth, J.D.; Trevaskis, J.L.; Turek, V.F.; Parkes, D.G. “Weighing in” on synergy: Preclinical research on neurohormonal anti-obesity combinations. Brain Res., 2010, 1350, 86-94.
[108]
Chatzigeorgiou, A.; Kandaraki, E.; Papavassiliou, A.G.; Koutsilieris, M. Peripheral targets in obesity treatment: A comprehensive update. Obes. Rev., 2014, 15(6), 487-503.
[109]
Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands. Drug Discov. Today, 2004, 9(15), 641-651.
[110]
Yu, H.; Jin, H.; Gong, W.; Wang, Z.; Liang, H. Pharmacological actions of multi-target-directed evodiamine. Molecules, 2013, 18(2), 1826-1843.
[111]
Martinez, J.A. Body-weight regulation: causes of obesity. Proc. Nutr. Soc., 2000, 59(3), 337-345.
[112]
Schoeller, D.A. The energy balance equation: Looking back and looking forward are two very different views. Nutr. Rev., 2009, 67(5), 249-254.
[113]
Gautron, L.; Elmquist, J.K.; Williams, K.W. Neural control of energy balance: Translating circuits to therapies. Cell, 2015, 161(1), 133-145.
[114]
Wilson, J.L.; Enriori, P.J. A talk between fat tissue, gut, pancreas and brain to control body weight. Mol. Cell. Endocrinol., 2015, 418(Pt 2), 108-119.
[115]
Fasshauer, M.; Blüher, M. Adipokines in health and disease. Trends Pharmacol. Sci., 2015, 36(7), 461-470.
[116]
Byrne, C.S.; Chambers, E.S.; Morrison, D.J.; Frost, G. The role of short chain fatty acids in appetite regulation and energy homeostasis. Int. J. Obes., 2015, 39(9), 1331-1338.
[117]
Greenway, F.L. Physiological adaptations to weight loss and factors favouring weight regain. Int. J. Obes., 2015, 39(8), 1188-1196.
[118]
Pucci, A.; Finer, N. New medications for treatment of obesity: Metabolic and cardiovascular effects. Can. J. Cardiol., 2015, 31(2), 142-152.
[119]
Martinez, J.A.; Milagro, F.I. Genetics of weight loss: A basis for personalized obesity management. Trends Food Sci. Technol., 2015, 42, 97-115.
[120]
Tentolouris, N.; Alexiadou, K.; Kokkinos, A.; Koukou, E.; Perrea, D.; Kyriaki, D.; Katsilambros, N. Meal-induced thermogenesis and macronutrient oxidation in lean and obese women after consumption of carbohydrate-rich and fat-rich meals. Nutrition, 2011, 27(3), 310-315.
[121]
Butsch, W.S. Obesity medications: what does the future look like? Curr. Opin. Endocrinol. Diabetes Obes., 2015, 22(5), 360-366.
[122]
Mordes, J.P.; Liu, C.; Xu, S. Medications for weight loss. Curr. Opin. Endocrinol. Diabetes Obes., 2015, 22(2), 91-97.
[123]
Guo, L.; Tabrizchi, R. Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance. Pharmacol. Ther., 2006, 111(1), 145-173.
[124]
Hsu, S.C.; Huang, C.J. Changes in liver PPARalpha mRNA expression in response to two levels of high-safflower-oil diets correlate with changes in adiposity and serum leptin in rats and mice. J. Nutr. Biochem., 2007, 18(2), 86-96.
[125]
Huang, T.H.; Peng, G.; Kota, B.P.; Li, G.Q.; Yamahara, J.; Roufogalis, B.D.; Li, Y. Pomegranate flower improves cardiac lipid metabolism in a diabetic rat model: role of lowering circulating lipids. Br. J. Pharmacol., 2005, 145(6), 767-774.
[126]
Li, Y.; Huang, T.H-W.; Yamahara, J. Salacia root, a unique Ayurvedic medicine, meets multiple targets in diabetes and obesity. Life Sci., 2008, 82(21-22), 1045-1049.
[127]
Jain, K.S.; Kathiravan, M.K.; Somani, R.S.; Shishoo, C.J. The biology and chemistry of hyperlipidemia. Bioorg. Med. Chem., 2007, 15(14), 4674-4699.
[128]
Pirat, C.; Farce, A.; Lebègue, N.; Renault, N.; Furman, C.; Millet, R.; Yous, S.; Speca, S.; Berthelot, P.; Desreumaux, P.; Chavatte, P. Targeting peroxisome proliferator-activated receptors (PPARs): Development of modulators. J. Med. Chem., 2012, 55(9), 4027-4061.
[129]
Okazaki, S.; Noguchi-Yachide, T.; Sakai, T.; Ishikawa, M.; Makishima, M.; Hashimoto, Y.; Yamaguchi, T. Discovery of N-(1-(3-(4-phenoxyphenyl)-1,2,4-oxadiazol-5-yl)ethyl)acetamides as novel acetyl-CoA carboxylase 2 (ACC2) inhibitors with peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonistic activity. Bioorg. Med. Chem., 2016, 24(21), 5258-5269.
[130]
Masuzaki, H.; Paterson, J.; Shinyama, H.; Morton, N.M.; Mullins, J.J.; Seckl, J.R.; Flier, J.S. A transgenic model of visceral obesity and the metabolic syndrome. Science, 2001, 294(5549), 2166-2170.
[131]
Hammer, F.; Stewart, P.M. Cortisol metabolism in hypertension. Best Pract. Res. Clin. Endocrinol. Metab., 2006, 20(3), 337-353.
[132]
Ge, R.; Huang, Y.; Liang, G.; Li, X. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development. Curr. Med. Chem., 2010, 17(5), 412-422.
[133]
Freund, T.F.; Katona, I.; Piomelli, D. Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev., 2003, 83(3), 1017-1066.
[134]
Cuchel, M.; Rader, D.J. Microsomal transfer protein inhibition in humans. Curr. Opin. Lipidol., 2013, 24(3), 246-250.
[135]
Roevens, P.; Heeres, J.; Meerpoel, L.; Dupont, A.; Borghys, H.; Lammens, L.; Auwerx, L.; Staels, B.; De Chaffoy De Courcelles, D. Hypolipidemic effects of R103757, a potent stereoselective inhibitor of microsomal triglyceride transfer protein (MTP). Atherosclerosis, 1999, 144(Suppl. 1), 38.
[136]
Gruetzmann, R.; Beuck, M.; Mueller, U.; Nielsch, U. Bay 13-9952 (implitapide), an inhibitor of microsomal triglyceride transfer protein (MTP), blocks secretion of Apo-B lipoproteins. Atherosclerosis, 2000, 151, 91-92.
[137]
Tao, Y.X. The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology. Endocr. Rev., 2010, 31(4), 506-543.
[138]
Wikberg, J.E.; Mutulis, F. Targeting melanocortin receptors: an approach to treat weight disorders and sexual dysfunction. Nat. Rev. Drug Discov., 2008, 7(4), 307-323.
[139]
Billes, S.K.; Sinnayah, P.; Cowley, M.A. Naltrexone/bupropion for obesity: An investigational combination pharmacotherapy for weight loss. Pharmacol. Res., 2014, 84, 1-11.
[140]
Kelly, M.J.; Loose, M.D.; Ronnekleiv, O.K. Opioids hyperpolarize beta-endorphin neurons via mu-receptor activation of a potassium conductance. Neuroendocrinology, 1990, 52(3), 268-275.
[141]
Cowley, M.A.; Smart, J.L.; Rubinstein, M.; Cerdán, M.G.; Diano, S.; Horvath, T.L.; Cone, R.D.; Low, M.J. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature, 2001, 411(6836), 480-484.
[142]
Ibrahim, N.; Bosch, M.A.; Smart, J.L.; Qiu, J.; Rubinstein, M.; Rønnekleiv, O.K.; Low, M.J.; Kelly, M.J. Hypothalamic proopiomelanocortin neurons are glucose responsive and express K(ATP) channels. Endocrinology, 2003, 144(4), 1331-1340.
[143]
Elias, C.F.; Lee, C.; Kelly, J.; Aschkenasi, C.; Ahima, R.S.; Couceyro, P.R.; Kuhar, M.J.; Saper, C.B.; Elmquist, J.K. Leptin activates hypothalamic CART neurons projecting to the spinal cord. Neuron, 1998, 21(6), 1375-1385.
[144]
Kalra, S.P.; Dube, M.G.; Pu, S.; Xu, B.; Horvath, T.L.; Kalra, P.S. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr. Rev., 1999, 20(1), 68-100.
[145]
Kanatani, A.; Mashiko, S.; Murai, N.; Sugimoto, N.; Ito, J.; Fukuroda, T.; Fukami, T.; Morin, N.; MacNeil, D.J.; Van der Ploeg, L.H.; Saga, Y.; Nishimura, S.; Ihara, M. Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice. Endocrinology, 2000, 141(3), 1011-1016.
[146]
Mashiko, S.; Moriya, R.; Ishihara, A.; Gomori, A.; Matsushita, H.; Egashira, S.; Iwaasa, H.; Takahashi, T.; Haga, Y.; Fukami, T.; Kanatani, A. Synergistic interaction between neuropeptide Y1 and Y5 receptor pathways in regulation of energy homeostasis. Eur. J. Pharmacol., 2009, 615(1-3), 113-117.
[147]
Carlini, V.P.; Varas, M.M.; Cragnolini, A.B.; Schiöth, H.B.; Scimonelli, T.N.; de Barioglio, S.R. Differential role of the hippocampus, amygdala, and dorsal raphe nucleus in regulating feeding, memory, and anxiety-like behavioral responses to ghrelin. Biochem. Biophys. Res. Commun., 2004, 313(3), 635-641.
[148]
Date, Y.; Murakami, N.; Toshinai, K.; Matsukura, S.; Niijima, A.; Matsuo, H.; Kangawa, K.; Nakazato, M. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology, 2002, 123(4), 1120-1128.
[149]
Naleid, A.M.; Grace, M.K.; Cummings, D.E.; Levine, A.S. Ghrelin induces feeding in the mesolimbic reward pathway between the ventral tegmental area and the nucleus accumbens. Peptides, 2005, 26(11), 2274-2279.
[150]
Korbonits, M.; Grossman, A.B. Ghrelin: Update on a novel hormonal system. Eur. J. Endocrinol., 2004, 151(Suppl. 1), S67-S70.
[151]
Theander-Carrillo, C.; Wiedmer, P.; Cettour-Rose, P.; Nogueiras, R.; Perez-Tilve, D.; Pfluger, P.; Castaneda, T.R.; Muzzin, P.; Schürmann, A.; Szanto, I.; Tschöp, M.H.; Rohner-Jeanrenaud, F. Ghrelin action in the brain controls adipocyte metabolism. J. Clin. Invest., 2006, 116(7), 1983-1993.
[152]
Jerlhag, E.; Egecioglu, E.; Dickson, S.L.; Douhan, A.; Svensson, L.; Engel, J.A. Ghrelin administration into tegmental areas stimulates locomotor activity and increases extracellular concentration of dopamine in the nucleus accumbens. Addict. Biol., 2007, 12(1), 6-16.
[153]
Skibicka, K.P.; Hansson, C.; Egecioglu, E.; Dickson, S.L. Role of ghrelin in food reward: impact of ghrelin on sucrose self-administration and mesolimbic dopamine and acetylcholine receptor gene expression. Addict. Biol., 2012, 17(1), 95-107.
[154]
Cummings, D.E.; Purnell, J.Q.; Frayo, R.S.; Schmidova, K.; Wisse, B.E.; Weigle, D.S. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes, 2001, 50(8), 1714-1719.
[155]
Callahan, H.S.; Cummings, D.E.; Pepe, M.S.; Breen, P.A.; Matthys, C.C.; Weigle, D.S. Postprandial suppression of plasma ghrelin level is proportional to ingested caloric load but does not predict intermeal interval in humans. J. Clin. Endocrinol. Metab., 2004, 89(3), 1319-1324.
[156]
Druce, M.R.; Wren, A.M.; Park, A.J.; Milton, J.E.; Patterson, M.; Frost, G.; Ghatei, M.A.; Small, C.; Bloom, S.R. Ghrelin increases food intake in obese as well as lean subjects. Int. J. Obes., 2005, 29(9), 1130-1136.
[157]
Adrian, T.E.; Ferri, G.L.; Bacarese-Hamilton, A.J.; Fuessl, H.S.; Polak, J.M.; Bloom, S.R. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology, 1985, 89(5), 1070-1077.
[158]
Onaga, T.; Zabielski, R.; Kato, S. Multiple regulation of peptide YY secretion in the digestive tract. Peptides, 2002, 23(2), 279-290.
[159]
le Roux, C.W.; Batterham, R.L.; Aylwin, S.J.; Patterson, M.; Borg, C.M.; Wynne, K.J.; Kent, A.; Vincent, R.P.; Gardiner, J.; Ghatei, M.A.; Bloom, S.R. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology, 2006, 147(1), 3-8.
[160]
Hort, Y.; Baker, E.; Sutherland, G.R.; Shine, J.; Herzog, H. Gene duplication of the human peptide YY gene (PYY) generated the pancreatic polypeptide gene (PPY) on chromosome 17q21.1. Genomics, 1995, 26(1), 77-83.
[161]
Larhammar, D. Structural diversity of receptors for neuropeptide Y, peptide YY and pancreatic polypeptide. Regul. Pept., 1996, 65(3), 165-174.
[162]
Adrian, T.E.; Bloom, S.R.; Bryant, M.G.; Polak, J.M.; Heitz, P.H.; Barnes, A.J. Distribution and release of human pancreatic polypeptide. Gut, 1976, 17(12), 940-944.
[163]
Asakawa, A.; Inui, A.; Yuzuriha, H.; Ueno, N.; Katsuura, G.; Fujimiya, M.; Fujino, M.A.; Niijima, A.; Meguid, M.M.; Kasuga, M. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology, 2003, 124(5), 1325-1336.
[164]
Reinehr, T.; Enriori, P.J.; Harz, K.; Cowley, M.A.; Roth, C.L. Pancreatic polypeptide in obese children before and after weight loss. Int. J. Obes., 2006, 30(10), 1476-1481.
[165]
Myers, M.G., Jr Leptin receptor signaling and the regulation of mammalian physiology. Recent Prog. Horm. Res., 2004, 59, 287-304.
[166]
Schwartz, M.W.; Seeley, R.J.; Woods, S.C.; Weigle, D.S.; Campfield, L.A.; Burn, P.; Baskin, D.G. Leptin increases hypothalamic pro-opiomelanocortin mRNA expression in the rostral arcuate nucleus. Diabetes, 1997, 46(12), 2119-2123.
[167]
Stephens, T.W.; Basinski, M.; Bristow, P.K.; Bue-Valleskey, J.M.; Burgett, S.G.; Craft, L.; Hale, J.; Hoffmann, J.; Hsiung, H.M.; Kriauciunas, A.; MacKellar, W.; Rosteck, P.R., Jr; Schoner, B.; Smith, D.; Tinsley, F.C.; Zhang, X-Y.; Heiman, M. The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature, 1995, 377(6549), 530-532.
[168]
Halaas, J.L.; Gajiwala, K.S.; Maffei, M.; Cohen, S.L.; Chait, B.T.; Rabinowitz, D.; Lallone, R.L.; Burley, S.K.; Friedman, J.M. Weight-reducing effects of the plasma protein encoded by the obese gene. Science, 1995, 269(5223), 543-546.
[169]
Campfield, L.A.; Smith, F.J.; Burn, P. The OB protein (leptin) pathway--A link between adipose tissue mass and central neural networks. Horm. Metab. Res., 1996, 28(12), 619-632.
[170]
Myers, M.G.; Cowley, M.A.; Münzberg, H. Mechanisms of leptin action and leptin resistance. Annu. Rev. Physiol., 2008, 70, 537-556.
[171]
Hommel, J.D.; Trinko, R.; Sears, R.M.; Georgescu, D.; Liu, Z.W.; Gao, X.B.; Thurmon, J.J.; Marinelli, M.; DiLeone, R.J. Leptin receptor signaling in midbrain dopamine neurons regulates feeding. Neuron, 2006, 51(6), 801-810.
[172]
Farooqi, I.S.; O’Rahilly, S. Monogenic obesity in humans. Annu. Rev. Med., 2005, 56, 443-458.
[173]
Tartaglia, L.A.; Dembski, M.; Weng, X.; Deng, N.; Culpepper, J.; Devos, R.; Richards, G.J.; Campfield, L.A.; Clark, F.T.; Deeds, J.; Muir, C.; Sanker, S.; Moriarty, A.; Moore, K.J.; Smutko, J.S.; Mays, G.G.; Wool, E.A.; Monroe, C.A.; Tepper, R.I. Identification and expression cloning of a leptin receptor, OB-R. Cell, 1995, 83(7), 1263-1271.
[174]
Lee, G.H.; Proenca, R.; Montez, J.M.; Carroll, K.M.; Darvishzadeh, J.G.; Lee, J.I.; Friedman, J.M. Abnormal splicing of the leptin receptor in diabetic mice. Nature, 1996, 379(6566), 632-635.
[175]
Ozcan, L.; Ergin, A.S.; Lu, A.; Chung, J.; Sarkar, S.; Nie, D.; Myers, M.G., Jr; Ozcan, U. Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab., 2009, 9(1), 35-51.
[176]
Cone, R.D. Anatomy and regulation of the central melanocortin system. Nat. Neurosci., 2005, 8(5), 571-578.
[177]
Woods, S.C.; Decke, E.; Vasselli, J.R. Metabolic hormones and regulation of body weight. Psychol. Rev., 1974, 81(1), 26-43.
[178]
Brange, J.; Langkjoer, L. Insulin structure and stability. Pharm. Biotechnol., 1993, 5, 315-350.
[179]
Menéndez, J.A.; Atrens, D.M. Insulin and the paraventricular hypothalamus: modulation of energy balance. Brain Res., 1991, 555(2), 193-201.
[180]
Palmiter, R.D. Is dopamine a physiologically relevant mediator of feeding behavior? Trends Neurosci., 2007, 30(8), 375-381.
[181]
Błajecka, K.; Borgström, A.; Arcaro, A. Phosphatidylinositol 3-kinase isoforms as novel drug targets. Curr. Drug Targets, 2011, 12(7), 1056-1081.
[182]
Di Gregorio, G.B.; Yao-Borengasser, A.; Rasouli, N.; Varma, V.; Lu, T.; Miles, L.M.; Ranganathan, G.; Peterson, C.A.; McGehee, R.E.; Kern, P.A. Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes, 2005, 54(8), 2305-2313.
[183]
Engelman, J.A. Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat. Rev. Cancer, 2009, 9(8), 550-562.
[184]
Hattori, Y.; Suzuki, K.; Hattori, S.; Kasai, K. Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension, 2006, 47(6), 1183-1188.
[185]
Pittner, R.A.; Albrandt, K.; Beaumont, K.; Gaeta, L.S.; Koda, J.E.; Moore, C.X.; Rittenhouse, J.; Rink, T.J. Molecular physiology of amylin. J. Cell. Biochem., 1994, 55(Suppl.), 19-28.
[186]
Koda, J.E.; Fineman, M.S.; Kolterman, O.G.; Caro, J.F. 24 hour plasma amylin profiles are elevated in IGT subjects vs normal controls. Diabetes, 1995, 44(Suppl. 1), 238A.
[187]
Lutz, T.A.; Mollet, A.; Rushing, P.A.; Riediger, T.; Scharrer, E. The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema/nucleus of the solitary tract (AP/NTS) lesioned rats. Int. J. Obes. Relat. Metab. Disord., 2001, 25(7), 1005-1011.
[188]
Rushing, P.A.; Hagan, M.M.; Seeley, R.J.; Lutz, T.A.; D’Alessio, D.A.; Air, E.L.; Woods, S.C. Inhibition of central amylin signaling increases food intake and body adiposity in rats. Endocrinology, 2001, 142(11), 5035.
[189]
Qi, Y.; Takahashi, N.; Hileman, S.M.; Patel, H.R.; Berg, A.H.; Pajvani, U.B.; Scherer, P.E.; Ahima, R.S. Adiponectin acts in the brain to decrease body weight. Nat. Med., 2004, 10(5), 524-529.
[190]
Kadowaki, T.; Yamauchi, T. Adiponectin and adiponectin receptors. Endocr. Rev., 2005, 26(3), 439-451.
[191]
Drucker, D.J. The biology of incretin hormones. Cell Metab., 2006, 3(3), 153-165.
[192]
Näslund, E.; King, N.; Mansten, S.; Adner, N.; Holst, J.J.; Gutniak, M.; Hellström, P.M. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br. J. Nutr., 2004, 91(3), 439-446.
[193]
Turton, M.D.; O’Shea, D.; Gunn, I.; Beak, S.A.; Edwards, C.M.; Meeran, K.; Choi, S.J.; Taylor, G.M.; Heath, M.M.; Lambert, P.D.; Wilding, J.P.; Smith, D.M.; Ghatei, M.A.; Herbert, J.; Bloom, S.R. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature, 1996, 379(6560), 69-72.
[194]
Flint, A.; Raben, A.; Ersbøll, A.K.; Holst, J.J.; Astrup, A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int. J. Obes. Relat. Metab. Disord., 2001, 25(6), 781-792.
[195]
MacDonald, P.E.; De Marinis, Y.Z.; Ramracheya, R.; Salehi, A.; Ma, X.; Johnson, P.R.; Cox, R.; Eliasson, L.; Rorsman, P.A.K. ATP channel-dependent pathway within alpha cells regulates glucagon release from both rodent and human islets of Langerhans. PLoS Biol., 2007, 5(6), e143.
[196]
Cryer, P.E. Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology, 2012, 153(3), 1039-1048.
[197]
Sadry, S.A.; Drucker, D.J. Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat. Rev. Endocrinol., 2013, 9(7), 425-433.
[198]
Nair, K.S. Hyperglucagonemia increases resting metabolic rate in man during insulin deficiency. J. Clin. Endocrinol. Metab., 1987, 64(5), 896-901.
[199]
Berryman, D.E.; Glad, C.A.; List, E.O.; Johannsson, G. The GH/IGF-1 axis in obesity: pathophysiology and therapeutic considerations. Nat. Rev. Endocrinol., 2013, 9(6), 346-356.
[200]
Johannsson, G. Management of adult growth hormone deficiency. Endocrinol. Metab. Clin. North Am., 2007, 36(1), 203-220.
[201]
Schwartz, M.W.; Woods, S.C.; Porte, D., Jr; Seeley, R.J.; Baskin, D.G. Central nervous system control of food intake. Nature, 2000, 404(6778), 661-671.
[202]
Wang, G.J.; Volkow, N.D.; Fowler, J.S. The role of dopamine in motivation for food in humans: implications for obesity. Expert Opin. Ther. Targets, 2002, 6(5), 601-609.
[203]
Yin, H.H.; Knowlton, B.J.; Balleine, B.W. Lesions of dorsolateral striatum preserve outcome expectancy but disrupt habit formation in instrumental learning. Eur. J. Neurosci., 2004, 19(1), 181-189.
[204]
Johnson, P.M.; Kenny, P.J. Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats. Nat. Neurosci., 2010, 13(5), 635-641.
[205]
Wang, G-J.; Geliebter, A.; Volkow, N.D.; Telang, F.W.; Logan, J.; Jayne, M.C.; Galanti, K.; Selig, P.A.; Han, H.; Zhu, W.; Wong, C.T.; Fowler, J.S. Enhanced striatal dopamine release during food stimulation in binge eating disorder. Obesity (Silver Spring), 2011, 19(8), 1601-1608.
[206]
Oltmans, G.A. Norepinephrine and dopamine levels in hypothalamic nuclei of the genetically obese mouse (ob/ob). Brain Res., 1983, 273(2), 369-373.
[207]
Leibowitz, S.F.; Roossin, P.; Rosenn, M. Chronic norepinephrine injection into the hypothalamic paraventricular nucleus produces hyperphagia and increased body weight in the rat. Pharmacol. Biochem. Behav., 1984, 21(5), 801-808.
[208]
Garfield, A.S.; Heisler, L.K. Pharmacological targeting of the serotonergic system for the treatment of obesity. J. Physiol., 2009, 587(1), 49-60.
[209]
Leibowitz, S.F.; Weiss, G.F.; Shor-Posner, G. Hypothalamic serotonin: pharmacological, biochemical, and behavioral analyses of its feeding-suppressive action. Clin. Neuropharmacol., 1988, 11(Suppl. 1), S51-S71.
[210]
Sargent, B.J.; Moore, N.A. New central targets for the treatment of obesity. Br. J. Clin. Pharmacol., 2009, 68(6), 852-860.
[211]
Minokoshi, Y.; Kim, Y.B.; Peroni, O.D.; Fryer, L.G.; Müller, C.; Carling, D.; Kahn, B.B. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature, 2002, 415(6869), 339-343.
[212]
Abu-Elheiga, L.; Matzuk, M.M.; Abo-Hashema, K.A.; Wakil, S.J. Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science, 2001, 291(5513), 2613-2616.
[213]
Kiens, B.; Alsted, T.J.; Jeppesen, J. Factors regulating fat oxidation in human skeletal muscle. Obes. Rev., 2011, 12(10), 852-858.
[214]
Dulloo, A.G. The search for compounds that stimulate thermogenesis in obesity management: from pharmaceuticals to functional food ingredients. Obes. Rev., 2011, 12(10), 866-883.
[215]
Alonso, A.; Sasin, J.; Bottini, N.; Friedberg, I.; Friedberg, I.; Osterman, A.; Godzik, A.; Hunter, T.; Dixon, J.; Mustelin, T. Protein tyrosine phosphatases in the human genome. Cell, 2004, 117(6), 699-711.
[216]
Elchebly, M.; Payette, P.; Michaliszyn, E.; Cromlish, W.; Collins, S.; Loy, A.L.; Normandin, D.; Cheng, A.; Himms-Hagen, J.; Chan, C.C.; Ramachandran, C.; Gresser, M.J.; Tremblay, M.L.; Kennedy, B.P. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science, 1999, 283(5407), 1544-1548.
[217]
Lee, S.; Wang, Q. Recent development of small molecular specific inhibitor of protein tyrosine phosphatase 1B. Med. Res. Rev., 2007, 27(4), 553-573.
[218]
Gum, R.J.; Gaede, L.L.; Koterski, S.L.; Heindel, M.; Clampit, J.E.; Zinker, B.A.; Trevillyan, J.M.; Ulrich, R.G.; Jirousek, M.R.; Rondinone, C.M. Reduction of protein tyrosine phosphatase 1B increases insulin-dependent signaling in ob/ob mice. Diabetes, 2003, 52(1), 21-28.
[219]
Nichols, A.J.; Mashal, R.D.; Balkan, B. Toward the discovery of small molecule PTP1B inhibitors for the treatment of metabolic diseases. Drug Dev. Res., 2006, 67(7), 559-566.
[220]
Sheng, H.; Sun, H. Synthesis, biology and clinical significance of pentacyclic triterpenes: a multi-target approach to prevention and treatment of metabolic and vascular diseases. Nat. Prod. Rep., 2011, 28(3), 543-593.
[221]
Houten, S.M.; Watanabe, M.; Auwerx, J. Endocrine functions of bile acids. EMBO J., 2006, 25(7), 1419-1425.
[222]
Kawamata, Y.; Fujii, R.; Hosoya, M.; Harada, M.; Yoshida, H.; Miwa, M.; Fukusumi, S.; Habata, Y.; Itoh, T.; Shintani, Y.; Hinuma, S.; Fujisawa, Y.; Fujino, M.A. G protein-coupled receptor responsive to bile acids. J. Biol. Chem., 2003, 278(11), 9435-9440.
[223]
Watanabe, M.; Houten, S.M.; Mataki, C.; Christoffolete, M.A.; Kim, B.W.; Sato, H.; Messaddeq, N.; Harney, J.W.; Ezaki, O.; Kodama, T.; Schoonjans, K.; Bianco, A.C.; Auwerx, J. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature, 2006, 439(7075), 484-489.
[224]
Katsuma, S.; Hirasawa, A.; Tsujimoto, G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem. Biophys. Res. Commun., 2005, 329(1), 386-390.
[225]
Rudel, L.L.; Lee, R.G.; Parini, P. ACAT2 is a target for treatment of coronary heart disease associated with hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol., 2005, 25(6), 1112-1118.
[226]
Smith, S.J.; Cases, S.; Jensen, D.R.; Chen, H.C.; Sande, E.; Tow, B.; Sanan, D.A.; Raber, J.; Eckel, R.H.; Farese, R.V. Jr Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat. Nat. Genet., 2000, 25(1), 87-90.
[227]
Yamamoto, T.; Yamaguchi, H.; Miki, H.; Kitamura, S.; Nakada, Y.; Aicher, T.D.; Pratt, S.A.; Kato, K. A novel coenzyme A: diacylglycerol acyltransferase 1 inhibitor stimulates lipid metabolism in muscle and lowers weight in animal models of obesity. Eur. J. Pharmacol., 2011, 650(2-3), 663-672.
[228]
Greenway, F.L.; Whitehouse, M.J.; Guttadauria, M.; Anderson, J.W.; Atkinson, R.L.; Fujioka, K.; Gadde, K.M.; Gupta, A.K.; O’Neil, P.; Schumacher, D.; Smith, D.; Dunayevich, E.; Tollefson, G.D.; Weber, E.; Cowley, M.A. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring), 2009, 17(1), 30-39.
[229]
Fleming, J.W.; McClendon, K.S.; Riche, D.M. New obesity agents: lorcaserin and phentermine/topiramate. Ann. Pharmacother., 2013, 47(7-8), 1007-1016.
[230]
Lee, S.; Sziklas, V.; Andermann, F.; Farnham, S.; Risse, G.; Gustafson, M.; Gates, J.; Penovich, P.; Al-Asmi, A.; Dubeau, F.; Jones-Gotman, M. The effects of adjunctive topiramate on cognitive function in patients with epilepsy. Epilepsia, 2003, 44(3), 339-347.
[231]
Bray, G.A.; Hollander, P.; Klein, S.; Kushner, R.; Levy, B.; Fitchet, M.; Perry, B.H. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes. Res., 2003, 11(6), 722-733.
[232]
Shukla, A.P.; Buniak, W.I.; Aronne, L.J. Treatment of obesity in 2015. J. Cardiopulm. Rehabil. Prev., 2015, 35(2), 81-92.
[233]
Herranz-López, M.; Olivares-Vicente, M.; Encinar, J.A.; Barrajón-Catalán, E.; Segura-Carretero, A.; Joven, J.; Micol, V. Multi-targeted molecular effects of Hibiscus sabdariffa polyphenols: An opportunity for a global approach to obesity. Nutrients, 2017, 9(8), e907.
[234]
Jiménez-Sánchez, C.; Olivares-Vicente, M.; Rodríguez-Pérez, C.; Herranz-López, M.; Lozano-Sánchez, J.; Segura-Carretero, A.; Fernández-Gutiérrez, A.; Encinar, J.A.; Micol, V. AMPK modulatory activity of olive-tree leaves phenolic compounds: Bioassay-guided isolation on adipocyte model and in silico approach. PLoS One, 2017, 12(3), e0173074.
[235]
Sasaki, T.; Mita, M.; Ikari, N.; Kuboyama, A.; Hashimoto, S.; Kaneko, T.; Ishiguro, M.; Shimizu, M.; Inoue, J.; Sato, R. Identification of key amino acid residues in the hTGR5-nomilin interaction and construction of its binding model. PLoS One, 2017, 12(6), e0179226.
[236]
Glisan, S.L.; Grove, K.A.; Yennawar, N.H.; Lambert, J.D. Inhibition of pancreatic lipase by black tea theaflavins: Comparative enzymology and in silico modeling studies. Food Chem., 2017, 216, 296-300.
[237]
Wu, M.; Li, Y.; Fu, X.; Wang, J.; Zhang, S.; Yang, L. Profiling the interaction mechanism of quinoline/quinazoline derivatives as MCHR1 antagonists: An in silico method. Int. J. Mol. Sci., 2014, 15(9), 15475-15502.
[238]
Baig, M.H.; Ahmad, K.; Adil, M.; Khan, Z.A.; Khan, M.I.; Lohani, M.; Khan, M.S.; Kamal, M.A. Drug discovery and in silico techniques: A mini-review. Enzyme Eng., 2014, 4, 123-133.
Download PDF Flyer